Favorable survival maintained in children who have myeloid leukemia associated with Down syndrome using reduced-dose chemotherapy on Children's Oncology Group trial A2971

Analysis of GATA1 mutations in Down syndrome transient myeloproliferative disorder and myeloid leukemia

(2011) K. A. Alford et al.   BLOOD

Natural history of transient myeloproliferative disorder clinically diagnosed in Down syndrome neonates: a report from the Children's Oncology Group Study A2971

(2011) A. S. Gamis et al.   BLOOD

Down syndrome and GATA1 mutations in transient abnormal myeloproliferative disorder: mutation classes correlate with progression to myeloid leukemia

(2010) R. Kanezaki et al.   BLOOD

Functional differences between myeloid leukemia-initiating and transient leukemia cells in Down's syndrome

(2010) J Chen et al.   LEUKEMIA

Continuous and high-dose cytarabine combined chemotherapy in children with down syndrome and acute myeloid leukemia: Report from the Japanese children's cancer and leukemia study group (JCCLSG) AML 9805 down study

(2010) Takashi Taga et al.   PEDIATRIC BLOOD & CANCER

Insights into the manifestations, outcomes, and mechanisms of leukemogenesis in Down syndrome

(2009) S. Malinge et al.   BLOOD

Mutational spectrum at GATA1 provides insights into mutagenesis and leukemogenesis in Down syndrome

(2009) D. C. Cabelof et al.   BLOOD

Acute megakaryoblastic leukaemia (AMKL) in children: a comparison of AMKL with and without Down syndrome

(2008) Asahito Hama et al.   BRITISH JOURNAL OF HAEMATOLOGY